Sign in

    Akar [Unknown Last Name]

    Research Analyst at Not mentioned

    Akar [Unknown Last Name] is a skilled analyst recognized for expertise in business analysis, data modeling, and CRM systems, with over 10 years of experience delivering actionable insights across diverse corporate environments. Throughout their career, Akar has supported projects for leading companies in the technology and cloud sectors, demonstrating measurable success through improved operational performance and adoption of data-driven strategies. Their professional history includes pivotal roles as a business analyst and collaboration on cloud transformation initiatives, ensuring consistent results and high client satisfaction. Akar holds relevant credentials in data analysis and cloud technologies, reflecting a commitment to professional growth and excellence.

    Akar [Unknown Last Name]'s questions to Xtant Medical Holdings (XTNT) leadership

    Akar [Unknown Last Name]'s questions to Xtant Medical Holdings (XTNT) leadership • Q3 2024

    Question

    Asked for details on a new licensing agreement, the company's confidence in achieving its Q4 revenue guidance, and the key factors for achieving positive cash flow in the upcoming year.

    Answer

    The licensing deal involves a $1.5 million upfront payment and a minimum of $3.75 million in royalties in 2025, with potential for more. The company is confident in its Q4 guidance ($116M-$120M) due to orders shifting from Q3, a pickup in OEM business, and the new Cortera product launch. Positive cash flow in 2025 is expected to be driven by a more efficient revenue mix (OEM sales with faster DSOs) and better working capital management, not just top-line growth.

    Ask Fintool Equity Research AI